Achieve Life Sciences (NASDAQ:ACHV) Shares Down 6.5% – What’s Next?

01 Oct 2026, 19:41 by Danessa Lincoln · The Markets Daily

Shares of Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Free Report) were down 6.5% during trading on Thursday. The stock traded as low as $7.61 and last traded at $7.5660. 759,830 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 1,357,409 shares. The stock had previously closed at $8.09.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Morgan Stanley started coverage on Achieve Life Sciences in a research note on Thursday, August 13th. They set an “overweight” rating and a $13.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Achieve Life Sciences in a report on Wednesday, August 19th. UBS Group reaffirmed a “buy” rating on shares of Achieve Life Sciences in a report on Wednesday, August 12th. Wall Street Zen downgraded Achieve Life Sciences from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a report on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $15.50.

Read Our Latest Stock Analysis on ACHV

Achieve Life Sciences Price Performance

The company has a debt-to-equity ratio of 0.87, a current ratio of 0.95 and a quick ratio of 0.95. The firm has a market capitalization of $778.54 million, a P/E ratio of -4.89 and a beta of 2.25. The company’s 50 day moving average price is $7.44 and its 200 day moving average price is $5.76.

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.64). As a group, sell-side analysts anticipate that Achieve Life Sciences, Inc. will post -0.91 EPS for the current fiscal year.

Insider Activity

In related news, Director Richard Stewart sold 20,626 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $8.49, for a total value of $175,114.74. Following the transaction, the director owned 208,249 shares in the company, valued at $1,768,034.01. This trade represents a 9.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. bought a new position in Achieve Life Sciences in the second quarter valued at approximately $49,725,000. venBio Partners LLC acquired a new position in Achieve Life Sciences in the second quarter valued at about $38,623,122. BlackRock Inc. bought a new position in Achieve Life Sciences during the second quarter worth about $34,426,000. Jupiter Topco LLC acquired a new position in shares of Achieve Life Sciences during the 2nd quarter worth about $17,964,000. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Achieve Life Sciences in the 2nd quarter valued at about $12,575,000. Institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences, Inc is a clinical-stage pharmaceutical company focused on developing and commercializing cytisinicline, an investigational therapy designed to help adults stop smoking and address nicotine dependence. The company is listed on the Nasdaq Capital Market under the symbol ACHV.